Načítá se...
The GLP-1 agonist, liraglutide, as a pharmacotherapy for obesity
There is a global obesity epidemic that will continue to be a financial burden on healthcare systems around the world. Tackling obesity through diet and exercise should always be the first intervention, but this has not proved to be effective for a large number of patients. Pharmacotherapeutic optio...
Uloženo v:
| Vydáno v: | Ther Adv Chronic Dis |
|---|---|
| Hlavní autoři: | , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
SAGE Publications
2015
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4772342/ https://ncbi.nlm.nih.gov/pubmed/26977279 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/2040622315620180 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|